Solitary plasmacytoma of bone and asymptomatic multiple myeloma

Blood

Volumn 96, Issue 6, 2000, Pages 2037-2044

  Dimopoulos, M A ^a   Moulopoulos, L A ^a   Maniatis, A ^a   Alexanian, R ^a  

^a NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; CD56 ANTIGEN; CORTICOSTEROID; CYTOKINE; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MELPHALAN; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BONE TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOGENESIS; CHROMOSOME ABERRATION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

EID: 0034665761     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.6.2037.h8002037_2037_2044     Document Type: Review

References (71)

1. Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone
2. Curability of solitary bone plasmacytoma
3. Comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone
4. Solitary plasmacytoma of bone vs. extramedullary plasmacytoma and their relationship to multiple myeloma
5. Solitary myeloma: Clinical and prognostic features of a review of 114 cases
6. Solitary plasmacytomas of the spine: A review of 84 cases
7. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone
8. Solitary bone plasmacytoma: Outcome and prognostic factors following radiotherapy
9. Extramedullary plasmacytomas and solitary plasma cell turnouts of bone
10. Solitary plasmacytoma of bone and soft tissue
11. Prognostic significance of osteopenia and immunoparesis at presentation in patients with solitary myeloma of bone
12. Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two different entities?
13. Plasmacytoma. Treatment results and conversion to myeloma
14. Solitary plasmacytoma of bone: Mayo Clinic experience
15. Medical tumors of the chest wall: Solitary plasmacytoma and Ewing's sarcoma
16. Bilateral demyelinating neuropathy in a solitary lytic and sclerotic myeloma of the proximal humerus
17. Localized and indolent myeloma
18. Solitary plasmacytoma of bone and soft tissue
19. Solitary plasmacytoma of the spine. Long-term clinical course
20. Solitary plasmacytoma of bone: Treatment, progression and survival
21. Radiotherapy in the treatment of solitary plasmacytoma
22. Solitary plasmacytoma of bone: Clinical features, treatment and survival
23. The role of radiation therapy in the treatment of solitary plasmacytomas
24. Smoldering multiple myeloma
25. A clinical staging system for multiple myeloma
26. Prognosis of asymptomatic multiple myeloma
27. Monoclonal gammopathies of undetermined significance
28. Differential diagnosis of monoclonal gammopathies
29. Solitary plasmacytoma of bone and asymptomatic multiple myeloma
30. Risk of disease progression in asymptomatic multiple myeloma
31. Changing clinical presentation of multiple myeloma
32. Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region l in Norway I
33. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I: A randomized study
34. A prognostic index for multiple myeloma
35. Chlorambucil in indolent chronic lymphocytic leukemia
36. Incidence and follow-up of asymptomatic multiple myeloma
37. Prognostic factors in low tumor mass asymptomatic myeloma
38. Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma
39. Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies
40. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma
41. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma
42. Stage t multiple myeloma: Value of MR imaging of the bone marrow in the determination of prognosis
43. Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma
44. Prognostic features of asymptomatic multiple myeloma
45. On behalf of the Intergroupe Francophone du Myeloma: Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma
46. 14q32 Translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma
47. Incidence of multiple myeloma in Olmsted Country, Minnesota: 1978 through 1990, with a review of the trend since 1945
48. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations
49. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes
50. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
51. Chromosomal analysis in multiple myeloma: Cytogenetic evidence of two different diseases
52. Interphase fluorescance in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance
53. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias
54. CD130 rather that CD126 expression is associated with disease activity in multiple myeloma
55. Soluble interleukin-6 receptor (sIL-6R), a new prognostic factor in multiple myeloma
56. Myeloma cells release soluble interleukin-6R-α in relation to disease progression by two distinct mechanisms: Alternative splicing and proteolytic cleavage
57. Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma
58. Comparison of interleukin-1β expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma
59. Interleukin-10 and GP 130 cytokines in human multiple myeloma
60. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma
61. CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease
62. Analysis of multidrug resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma
63. Bone marrow angiogenesis and progression in multiple myeloma
64. Bone marrow neovascularization plasma cell angiogenic potential and matrix metalloproteinese-2 secretion parallel progression of human multiple myeloma
65. Antitumor activity of thalidomide in refractory multiple myeloma
66. Clinical and biological activity of thalidomide (THAL) in multiple myeloma (MM)
67. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferation disorders
68. Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: A prospective study of 87 bone biopsies
69. Mechanisms of polyclonal hypogammaglobulinemia in multiple myeloma
70. + B cells precede the diagnosis of multiple myeloma